AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
10 juin 2024 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
03 juin 2024 09h15 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
31 mai 2024 08h30 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single...
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
20 mai 2024 09h15 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in...
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
16 mai 2024 07h30 HE
|
AIM ImmunoTech Inc.
Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May...
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
09 mai 2024 08h50 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the...
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
06 mai 2024 08h30 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical...
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
29 avr. 2024 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has taken an essential step forward in testing the...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
25 avr. 2024 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
18 avr. 2024 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...